Lataa...
Eculizumab and Recurrent C3 Glomerulonephritis
BACKGROUND AND OBJECTIVES: Hyperactivity of the alternative complement pathway is the principle defect in the C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex, has been shown to be beneficial in some patients with this...
Tallennettuna:
| Julkaisussa: | Pediatr Nephrol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428658/ https://ncbi.nlm.nih.gov/pubmed/23689905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-013-2503-y |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|